"
Team:UCSF/Safety
From 2012.igem.org
| Line 28: | Line 28: | ||
did you document these issues in the Registry? how did you manage to handle the safety issue? How could other teams learn from your experience? | did you document these issues in the Registry? how did you manage to handle the safety issue? How could other teams learn from your experience? | ||
</h3orange1> | </h3orange1> | ||
| - | <p> <regulartext1> While one of our systems is a “toxin-anti-toxin” system, it occurs naturally in E. coli and does not effect other organisms in a toxic manner. Many researchers have used these toxins without further <a href=http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001281>(For example, Ariel Erental of the Institute for Medical Research Israel-Canada)</a> <br> We are entering in new pairs of toxin anti-toxin pairs, but the parts registry already documents a pair of toxin-antitoxin from E. coli: <a href=http://partsregistry.org/Part:BBa_K185004>RelE Toxin<a/>. </regulartext1> | + | <p> <regulartext1> While one of our systems is a “toxin-anti-toxin” system, it occurs naturally in <i>E. coli<i/> and does not effect other organisms in a toxic manner. Many researchers have used these toxins without further precautions <a href=http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001281>(For example, Ariel Erental of the Institute for Medical Research Israel-Canada)</a> <br> We are entering in new pairs of toxin anti-toxin pairs, but the parts registry already documents a pair of toxin-antitoxin from <i>E. coli<i/>: <a href=http://partsregistry.org/Part:BBa_K185004>RelE Toxin<a/>. </regulartext1> |
</div> | </div> | ||
| Line 34: | Line 34: | ||
<div id="description" style = "width:600px; height:250px"> | <div id="description" style = "width:600px; height:250px"> | ||
<h3orange1>3. Is there a local biosafety group, committee, or review board at your institution? If yes, what does your local biosafety group think about your project? If no, which specific biosafety rules or guidelines do you have to consider in your country? </h3orange1> | <h3orange1>3. Is there a local biosafety group, committee, or review board at your institution? If yes, what does your local biosafety group think about your project? If no, which specific biosafety rules or guidelines do you have to consider in your country? </h3orange1> | ||
| - | <p> <regulartext1> The UCSF iGEM Team works under the Biological Use Agreement (BUA) approved by UCSF Health and Safety (EH&S). http://industry.ucsf.edu/ehs/8046-DSY/version/default/part/4/data/ <p> | + | <p> <regulartext1> <FONT COLOR="black"> The UCSF iGEM Team works under the Biological Use Agreement (BUA) approved by UCSF Health and Safety (EH&S). http://industry.ucsf.edu/ehs/8046-DSY/version/default/part/4/data/ <p> |
| - | + | UCSF has a Biosafety Committee (http://or.ucsf.edu/ehs/7240-DSY/7422-DSY/8777), but it was not deemed necessary to meet with them regarding our project because all of our work falls under standard laboratory procedures that have prescribed regulations and safety protocols. </regulartext1> | |
<p> <regulartext1> Additionally, the United States has a manual with biosafety guidelines for biological laboratories: http://www.cdc.gov/biosafety/publications/bmbl5/index.htm </regulartext1> | <p> <regulartext1> Additionally, the United States has a manual with biosafety guidelines for biological laboratories: http://www.cdc.gov/biosafety/publications/bmbl5/index.htm </regulartext1> | ||
Revision as of 23:25, 7 September 2012
We are entering in new pairs of toxin anti-toxin pairs, but the parts registry already documents a pair of toxin-antitoxin from E. coli: RelE Toxin.
UCSF has a Biosafety Committee (http://or.ucsf.edu/ehs/7240-DSY/7422-DSY/8777), but it was not deemed necessary to meet with them regarding our project because all of our work falls under standard laboratory procedures that have prescribed regulations and safety protocols.
